Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3

Group 1 - Aristotle Capital Boston, LLC reported strong performance in small-cap equities, with the Russell 2000 Index reaching an all-time high since November 2021, driven by a favorable macroeconomic environment [1] - The Small Cap Equity Fund (Class I-2) returned 3.16% in Q3 2025, underperforming the Russell 2000 Index's total return of 12.39% [1] - The fund highlighted Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) as a key stock, which saw a one-month return of 8.74% and a 52-week gain of 39.09% [2] Group 2 - Supernus Pharmaceuticals, Inc. is a Maryland-based specialty pharmaceutical company focused on central nervous system diseases, reporting strong quarterly results that exceeded analyst expectations and raised fiscal year 2025 forecasts [3] - The company reported total revenue of $192.1 million in Q3 2025, an increase from $175.7 million in Q3 2024 [4] - Despite its potential, Supernus Pharmaceuticals is not among the top 30 most popular stocks among hedge funds, with 29 hedge fund portfolios holding its stock at the end of Q3 2025, up from 25 in the previous quarter [4]